MedPath

Dihydroergotamine Mesylate

The solution used in Dihydroergotamine Mesylate Nasal Spray (4 mg/mL) is intended for intranasal use and must not be injected.Rx Only

Approved
Approval ID

9ffe6d5a-7348-0498-e053-2a95a90a97a8

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 24, 2023

Manufacturers
FDA

Hikma Pharmaceuticals USA Inc.

DUNS: 118707839

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Dihydroergotamine Mesylate

PRODUCT DETAILS

NDC Product Code24201-463
Application NumberANDA211393
Marketing CategoryC73584
Route of AdministrationNASAL
Effective DateApril 24, 2023
Generic NameDihydroergotamine Mesylate

INGREDIENTS (5)

CAFFEINEInactive
Code: 3G6A5W338E
Classification: IACT
ANHYDROUS DEXTROSEInactive
Code: 5SL0G7R0OK
Classification: IACT
CARBON DIOXIDEInactive
Code: 142M471B3J
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
DIHYDROERGOTAMINE MESYLATEActive
Quantity: 4 mg in 1 mL
Code: 81AXN7R2QT
Classification: ACTIB
© Copyright 2025. All Rights Reserved by MedPath
Dihydroergotamine Mesylate - FDA Approval | MedPath